http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100269832-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2f21f475fb8289f608cd25f6010534ce http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_428bfa6ad074bbc7474459323fb5c8f4 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D221-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-416 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 |
| filingDate | 1993-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2000-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_976cd9d79c526ac380e87252830bbe77 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2f64bf98431feb2333bbb735ac5b5d9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b19aab36545b78352674a78ad9c7afce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57312c096d5d3cd8b57f0695083cd561 |
| publicationDate | 2000-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100269832-B1 |
| titleOfInvention | 2-aminoalkyl-5-aminoalkylamino substituted isoquininodazole-6- (2H) -ones having oncogenic activity and methods for preparing the same |
| abstract | The present invention relates to compounds of formula (I) below as free base and salts with pharmaceutically acceptable acids.n n n n n n n n In the above formula,n n n R is hydrogen or hydroxy;n n n One of X and Y is a carbon atom and the other is a nitrogen atom,n n n Provided that when Y is nitrogen, R is hydrogen;n n n A and B are the same or different and are C 1 -C 10 alkyl or phenylalkyl;n n n C 2 -C 10 alkyl having one or two substituents selected from the group consisting of OR 1 and NR 2 R 3 ; And from a group of C 2 -C 10 alkyl interrupted by one or two oxygen atoms or one-NR 4 -group and optionally substituted by one or two hydroxy (OH) or NR 2 R 3 groups Selected;n n n R 1 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, phenyl, phenylalkyl, -S (O 2 ) R 5 , C 2 -C 6 alkyl optionally substituted by NR 2 R 3 ;n n n R 2 and R 3 may be the same or different and consist of hydrogen, C 1 -C 10 alkyl, phenylalkyl, phenyl, C 2 -C 10 alkyl substituted by one or two hydroxy (0H) groups Or a 2- or 6-membered aromatic or non-aromatic heterocyclic ring, wherein R 2 and R 3 optionally contain an ethyleneimine ring or other heteroatom such as sulfur, oxygen or nitrogen together with the nitrogen atom to which they are attached; Forming;n n n R 4 is hydrogen, C l -C 10 alkyl, C 2 -C 10 hydroxyalkyl, NR 2 is substituted by C 2 -C 10 alkyl, R 3 is selected from the group consisting of phenylalkyl and phenyl;n n n R 5 is selected from the group consisting of C 1 -C 10 alkyl and phenylalkyl.n n n This compound has been shown to have oncogenic activity. |
| priorityDate | 1992-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 231.